Cargando…
Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells
The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern. In this study, we investigated the role of lncRNA TP53TG1 in the efficacy of sorafenib in HCC cells. We found that treatment with...
Autores principales: | Lu, Qingchun, Xin, Mingyang, Guo, Qian, Rothberg, Brad S., Gamero, Ana M., Yang, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414591/ https://www.ncbi.nlm.nih.gov/pubmed/36005829 http://dx.doi.org/10.3390/ncrna8040061 |
Ejemplares similares
-
LncRNA TP53TG1 Promotes the Growth and Migration of Hepatocellular Carcinoma Cells via Activation of ERK Signaling
por: Lu, Qingchun, et al.
Publicado: (2021) -
Modulation of Colorectal Tumor Behavior via lncRNA TP53TG1-Lipidic Nanosystem
por: Masoumi, Farimah, et al.
Publicado: (2021) -
Systematic analyses identify the anti-fibrotic role of lncRNA TP53TG1 in IPF
por: Sun, Jian, et al.
Publicado: (2022) -
TP53 Mutation Related and Directly Regulated lncRNA Prognosis Markers in Hepatocellular Carcinoma
por: Zhang, Xiulei, et al.
Publicado: (2021) -
LncRNA TP53TG1 plays an anti-oncogenic role in cervical cancer by synthetically regulating transcriptome profile in HeLa cells
por: Cheng, Yi, et al.
Publicado: (2022)